Acepodia Biotech, Inc.
🇺🇸United States
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06415487
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
🇨🇳Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05653271
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04319757
- Locations
- 🇺🇸
Northwestern Univeristy, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Taipei Veteran General Hospital, Taipei, Taiwan
© Copyright 2024. All Rights Reserved by MedPath